Back to top

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics today and set a price target of $19.00. According to TipR...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sarepta Therapeutics, Inc. (SRPT)